新诊断多发性骨髓瘤患者细胞遗传学异质性的预后意义
本研究基于HOVON-65/GMMG-HD4三期试验,用间期荧光原位杂交(iFISH)检测新诊断多发性骨髓瘤(MM)患者的亚克隆细胞遗传学异常(CA)。亚克隆CA具有重要预后意义:硼替佐米可完全克服无亚克隆高危CA患者的不良预后,但在有额外亚克隆CA的患者中不能。
要点
- 亚克隆CA在新诊断MM中具有重要预后意义。
- 硼替佐米完全克服无亚克隆高危CA患者的不良预后。
- 有额外亚克隆CA的高危患者,硼替佐米未能克服不良预后。
核心结论
- 由亚克隆CA定义的细胞遗传学异质性,在接受硼替佐米治疗的新诊断MM患者中具有重要预后意义。
研究设计与样本
- 研究纳入HOVON-65/GMMG-HD4三期试验中新诊断MM患者,采用间期荧光原位杂交(iFISH)检测亚克隆细胞遗传学异常(CA)。
- 患者接受3周期长春新碱、阿霉素和地塞米松或硼替佐米、阿霉素和地塞米松治疗,随后在串联自体移植后接受沙利度胺或硼替佐米维持治疗。
- 亚克隆定义为同一染色体位点拷贝数不同和/或与主克隆CA相比存在于至少少30%且最多2/3细胞中的CA。
主要发现
- 有亚克隆的患者中高危主克隆异常比例为31.0%,高超二倍体主克隆异常比例为24.8%,均高于主克隆为t(11;14)的患者(10.1%)。
- c-MYC获得和缺失是仅有的作为亚克隆出现频率(分别为8.1%和20.5%)高于主克隆(分别为6.2%和3.9%)的CA。
- 无亚克隆的高危CA患者接受硼替佐米治疗后,其不良预后被完全克服;但有额外亚克隆CA的患者未能克服。
- 未接受硼替佐米的高危患者,无论是否存在亚克隆,结局均不佳。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigated subclonal cytogenetic aberrations (CA) detected by interphase fluorescence in situ hybridization (iFISH) in patients with newly diagnosed multiple myeloma (MM) enrolled in the Haemato Oncology Foundation for Adults in the Netherlands (HOVON)-65/German-Speaking MM Group (GMMG)-HD4 phase 3 trial. Patients were either treated with 3 cycles of vincristine, Adriamycin, and dexamethasone or bortezomib, Adriamycin, and dexamethasone and then thalidomide or bortezomib maintenance after tandem autologous transplantation. Subclones were defined either by presence of different copy numbers of the same chromosome loci and/or CA present in at least 30% less and maximally 2/3 of cells compared with the main clone CA. Patients with subclones harbored more frequently high risk (31.0%) or hyperdiploid main clone aberrations (24.8%) than patients with t(11;14) in the main clone (10.1%). Gains and deletions of c-MYC were the only CA that occurred more frequently as subclone (8.1%/20.5%) than main clone (6.2%/3.9%, respectively). Treatment with bortezomib completely overcame the negative prognosis of high-risk CA in patients without subclones, but not in patients with additional subclonal CA. High-risk patients treated without bortezomib showed dismal outcome whether subclones were present or not. Cytogenetic heterogeneity defined by subclonal CA is of major prognostic significance in newly diagnosed MM patients treated with bortezomib within the HOVON-65/GMMG-HD4 trial.
引用
- Merz M, Jauch A, Hielscher T, et al. Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood Adv. 2017. PMID: 29344579. doi:10.1182/bloodadvances.2017013334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。